{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:10:50Z","timestamp":1791947450003,"version":"4.3.4"},"reference-count":50,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic inflammation may be a key driving force in the development and progression of Philadelphia chromosome\u2013negative myeloproliferative neoplasms (MPNs). Statins, commonly used to lower cholesterol, also possess antiproliferative, proapoptotic, and anti-inflammatory properties that may be beneficial in the treatment of patients with MPN. This retrospective cohort study investigated whether statin use, in addition to standard cytoreductive therapy, shortens the time required to achieve hematological and molecular responses, while allowing for lower cytoreductive drug dosages. A total of 129 patients were included, with 53 receiving statins from diagnosis. The study found that statin users achieved complete hematological response (CHR) significantly faster than nonusers (median time: 8 vs 18 months; hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.4-3.1; P = .0003). Among patients treated with pegylated interferon-alfa2 (IFN-\u03b12), the CHR rate was 97% in statin users vs 83% in nonusers (HR, 2.5; 95% CI, 1.5-3.9; P = .0004), and a higher proportion of statin users sustained CHR throughout follow-up. Additionally, IFN-treated statin users received a significantly lower mean dose of IFN-\u03b12. A dose-response relationship was observed, with higher statin intensity associated with an increase of CHR. Furthermore, statin use was significantly associated with achieving a partial molecular response among IFN-\u03b12-treated patients (HR, 2.6; 95% CI, 1.1-6.0; P = .029). No significant association was observed in hydroxyurea (HU)-treated patients. These findings suggest that statins may enhance the efficacy of IFN-\u03b12 in patients with MPN, while their benefit in HU-treated patients remains unclear. Prospective studies are warranted to further explore the therapeutic potential of statins in MPNs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017016","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:14:01Z","timestamp":1758222841000},"page":"6189-6198","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0515-8432","authenticated-orcid":false,"given":"Isabella Diana","family":"Davidsen","sequence":"first","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"},{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"L\u00f6ffler","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"},{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-7826","authenticated-orcid":false,"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-3099","authenticated-orcid":false,"given":"Trine Alma","family":"Knudsen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-1595","authenticated-orcid":false,"given":"Anders Lindholm","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-0440","authenticated-orcid":false,"given":"Sarah Friis","family":"Christensen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cordua","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-0555","authenticated-orcid":false,"given":"Christina Schjellerup","family":"Eickhardt-Dalb\u00f8ge","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-6766","authenticated-orcid":false,"given":"Marie Hvelplund","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"4Department of Clinical Biochemistry, Zealand University Hospital, K\u00f8ge, Denmark"},{"name":"5Department of Pathology, Harvard Medical School, Boston, MA"},{"name":"6Department of Laboratory Medicine, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-1105","authenticated-orcid":false,"given":"Troels","family":"Wienecke","sequence":"additional","affiliation":[{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"3Department of Neurology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"},{"name":"2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"22","key":"2025120910563784500_bib1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2025120910563784500_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"48","key":"2025120910563784500_bib3","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","author":"Clendening","year":"2012","journal-title":"Oncogene"},{"issue":"112","key":"2025120910563784500_bib4","first-page":"413","article-title":"Statins as anti-cancer therapy; can we translate preclinical and epidemiologic data into clinical benefit?","volume":"20","author":"Chae","year":"2015","journal-title":"Discov Med"},{"issue":"12","key":"2025120910563784500_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2025120910563784500_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/rheumatology\/ken466","article-title":"Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes","volume":"48","author":"Montecucco","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"24","key":"2025120910563784500_bib7","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehl277","article-title":"Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome","volume":"27","author":"Link","year":"2006","journal-title":"Eur Heart J"},{"issue":"23","key":"2025120910563784500_bib8","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2025120910563784500_bib9","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2025120910563784500_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025120910563784500_bib11","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"2025120910563784500_bib12","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2025120910563784500_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"2025120910563784500_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12103","article-title":"JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth","volume":"160","author":"Griner","year":"2013","journal-title":"Br J Haematol"},{"issue":"14","key":"2025120910563784500_bib15","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2025120910563784500_bib16","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"2025120910563784500_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","article-title":"The impact of statins on the intensity of phlebotomies in polycythemia vera","volume":"99","author":"Kre\u010dak","year":"2020","journal-title":"Ann Hematol"},{"key":"2025120910563784500_bib18","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"5","key":"2025120910563784500_bib19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"2025120910563784500_bib20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"14","key":"2025120910563784500_bib21","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2025120910563784500_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"issue":"25","key":"2025120910563784500_bib23","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025120910563784500_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025120910563784500_bib25","doi-asserted-by":"crossref","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a driver of clonal evolution in myeloproliferative neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"3","key":"2025120910563784500_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression. and symptoms","volume":"14","author":"Mendez Luque","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"2025120910563784500_bib27","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1002\/cam4.1815","article-title":"Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Cancer Med"},{"issue":"9","key":"2025120910563784500_bib28","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2025120910563784500_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"12","key":"2025120910563784500_bib30","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","article-title":"New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms","volume":"5","author":"Hasselbalch","year":"2021","journal-title":"Hemasphere"},{"issue":"8","key":"2025120910563784500_bib31","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cam4.1619","article-title":"Safety and efficacy of combination therapy of interferon-\u03b12 and ruxolitinib in polycythemia vera and myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med"},{"issue":"20","key":"2025120910563784500_bib32","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","article-title":"Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera","volume":"8","author":"S\u00f8rensen","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2025120910563784500_bib33","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3324\/haematol.2020.256602","article-title":"Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?","volume":"105","author":"Silver","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"2025120910563784500_bib34","first-page":"73","article-title":"Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera","volume":"3","author":"Bj\u00f8rn","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"10","key":"2025120910563784500_bib35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk Res"},{"key":"2025120910563784500_bib36","doi-asserted-by":"crossref","first-page":"101088","DOI":"10.1016\/j.redox.2018.101088","article-title":"Statin treatment, oxidative stress and inflammation in a Danish population","volume":"21","author":"S\u00f8rensen","year":"2019","journal-title":"Redox Biol"},{"issue":"5","key":"2025120910563784500_bib37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2025120910563784500_bib38","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2025120910563784500_bib39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"2025120910563784500_bib40","unstructured":"Sundhedsstyrelsen\n          . Anbefalinger om alkohol. 2023. Accessed 2 December 2023. https:\/\/sst.dk\/da\/borger\/en-sund-hverdag\/alkohol\/anbefalinger-om-alkohol."},{"issue":"25","key":"2025120910563784500_bib41","first-page":"e1046","article-title":"2019 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"13","key":"2025120910563784500_bib42","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2025120910563784500_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"2025120910563784500_bib44","doi-asserted-by":"crossref","first-page":"e70137","DOI":"10.1002\/hem3.70137","article-title":"(S219) JAK2V617F molecular response correlates with event-free survival in an early polycythemia vera population","volume":"9","author":"Kiladjian","year":"2025","journal-title":"Hemasphere"},{"issue":"19","key":"2025120910563784500_bib45","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025120910563784500_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jhep.2006.01.037","article-title":"Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway","volume":"45","author":"Di Bona","year":"2006","journal-title":"J Hepatol"},{"issue":"1","key":"2025120910563784500_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.17130","article-title":"Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study","volume":"193","author":"S\u00f8rensen","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"2025120910563784500_bib48","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2023021503","article-title":"Moving toward disease modification in polycythemia vera","volume":"142","author":"Bewersdorf","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025120910563784500_bib49","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"9","key":"2025120910563784500_bib50","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1002\/hem3.70003","article-title":"Are we ready for disease modification in myeloproliferative neoplasms?","volume":"8","author":"Harrison","year":"2024","journal-title":"Hemasphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6189\/2443138\/blooda_adv-2025-017016-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6189\/2443138\/blooda_adv-2025-017016-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:56:50Z","timestamp":1765295810000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/6189\/547306\/Statins-enhance-the-efficacy-of-pegylated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":50,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017016","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,12,2]]}}}